title: [Optimization of Immunosuppression and the Prevention of Fungal Infection in Autoimmune Diseases].
abstract: Mycophenolate mofetil (MMF) has recently been reported to be effective in the treatment of systemic lupus erythematosus (SLE). The therapeutic range of mycophenolic acid (MPA) and its 7-O-glucuronide (MPAG), and factors affecting their pharmacokinetics, remain to be clarified. The influence of the pharmacokinetics of MPA and MPAG on the activity of inosine 5'-monophosphate dehydrogenase (IMPDH), a target of the MPA, also remains to be revealed. The pharmacokinetic variability of hydroxy-itraconazole (OH-ITZ), an active metabolite of itraconazole frequently co-administered with immunosuppressants in immunocompromised patients, is not fully known. The aim of this study was to establish the optimal dosage and administration of immunosuppressants and antifungal agents. MMF improved clinical laboratory markers and reduced prednisolone dosage in 31 SLE patients, with a pre-dose plasma concentration of MPA and MPAG in the interquartile ranges of 0.94-2.96 and 18.6-53.7 μg/mL, respectively. Renal function and co-administered metal influenced the pharmacokinetics of MPA and MPAG in 31 SLE patients in the remission maintenance phase. IMPDH activity was induced in 29 SLE patients receiving the MMF therapy. This induction was dependent on the plasma concentration of MPAG, but not MPA. In addition, IMPDH activity was negatively correlated with complement fraction C3. MPA exposure and disease activity in SLE patients may determine IMPDH activity. The pharmacokinetic variability of OH-ITZ was associated with saturated metabolism to keto-itraconazole, serum concentration of albumin, and renal function in 46 immunocompromised patients. Prevention of fungal infections and drug-drug interactions in immunocompromised patients can be obtained by considering these identified confounding factors.
authors.affiliation: Department of Hospital Pharmacy, Hamamatsu University School of Medicine.
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Mino
mesh_terms: D003176:Complement C3 / Q000378:metabolism; D004347:Drug Interactions; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D020719:Glucuronides / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D006801:Humans; D007168:IMP Dehydrogenase / Q000378:metabolism; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics*; D007206:Individuality; D017964:Itraconazole / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control*; D011239:Prednisolone / Q000008:administration & dosage
chemical_list: D003176:Complement C3; D020719:Glucuronides; D007166:Immunosuppressive Agents; D017964:Itraconazole; C113145:mycophenolic acid glucuronide; D011239:Prednisolone; D007168:IMP Dehydrogenase; D009173:Mycophenolic Acid